Stage I of Phase II study assessing efficacy, safety and tolerability of barasertib (AZD1152) versus LDAC in elderly AML patients

類似資料

• Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
  著者:: Kantarjian, Hagop M, 等
  出版事項: (2013)
• Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
  著者:: Löwenberg, Bob, 等
  出版事項: (2011)
• Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
  著者:: Dennis, Mike, 等
  出版事項: (2012)
• Barasertib (AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo
  著者:: Helfrich, Barbara A, 等
  出版事項: (2016)
• AZD1152 rapidly and negatively affects the growth and survival of Human AML cells in vitro and in vivo
  著者:: Oke, Adedayo, 等
  出版事項: (2009)